2025 ICD-10-CM Diagnosis Code C88.0

by

Waldenström macroglobulinemia

  • C88.0 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • Short description: Waldenstrom macroglobulinemia
  • ICD-10-CM C88.0 is a new 2025 ICD-10-CM code that became effective on October 1, 2024.
  • This is the American ICD-10-CM version of C88.0 – other international versions of ICD-10 C88.0 may differ.

Applicable To

  • Lymphoplasmacytic lymphoma with IgM-production
  • Macroglobulinemia (idiopathic) (primary)

Type 1 Excludes

  • small cell B-cell lymphoma (C83.0)

The following code(s) above C88.0 contain annotation back-references

 that may be applicable to C88.0:

  • C00-D49  Neoplasms
  • C81-C96  Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C88  Malignant immunoproliferative diseases and certain other B-cell lymphomas

Approximate Synonyms

  • Macroglobulinemia
  • Waldenstrˆm macroglobulinemia
  • Waldenstroms macroglobulinemia

Clinical Information

  • (mak-ro-glob-u-li-ne-me-uh) a condition in which the blood contains high levels of large proteins and is too thick to flow through small blood vessels. One type is waldenstrom’s macroglobulinemia, which is a type of cancer.
  • A clonal neoplasm of small b-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum igm paraprotein. Lymphoplasmacytic lymphoma/waldenstrom’s macroglobulinemia is a relatively rare condition accounting for approximately 2% of hematologic malignancies. Symptoms include: weakness and fatigue, hemorrhagic manifestations, weight loss, and visual disturbances. Physical findings include: hepatomegaly, splenomegaly, fundic changes, adenopathy, neurologic abnormalities, and purpura. The most common laboratory finding is anemia. Treatment includes: chemotherapy (alkylating agents, nucleoside analogues) radiotherapy, and plasmapheresis. Bone marrow transplant is being investigated. Asymptomatic patients may be monitored without treatment until complications occur.
  • A lymphoproliferative disorder characterized by pleomorphic b-lymphocytes including plasma cells, with increased levels of monoclonal serum immunoglobulin m. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include anemia; hemorrhages; and hyperviscosity.
  • A rare cancer of the lymph cells that causes the body to produce abnormal levels of plasma cells (plasmacytosis) and lymphocytes (lymphocytosis) in the bone marrow. Waldenstrom’s macroglobulinemia may also cause a decrease in the number of red blood cells (anemia) and enlargement of the liver (hepatomegaly), spleen (splenomegaly), or glands (adenopathy).
  • An indolent (slow-growing) type of non-hodgkin lymphoma marked by abnormal levels of igm antibodies in the blood and an enlarged liver, spleen, or lymph nodes.
  • Lymphoplasmacytic lymphoma associated with bone marrow involvement and igm monoclonal gammopathy.
  • Plasma cell dyscrasia resembling leukemia, with cells of lymphocytic, plasmacytic, or intermediate morphology, that secrete an igm monoclonal component.

Code History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change
  • 2025 (effective 10/1/2024): Deleted code
  • 2025 (effective 10/1/2024): New code

Diagnosis Index entries containing back-references to C88.0:

error: Content is protected !!